Spironolactone vs placebo, Bisoprolol, and Doxazin to Determine the Optimal Treatment for drug-resistant Hypertention (PATHWAY-2) : a randomized, double blind, crossover trial.

Image of Spironolactone vs placebo, Bisoprolol, and Doxazin to Determine the Optimal Treatment for drug-resistant Hypertention (PATHWAY-2) : a randomized, double blind, crossover trial.

THERAPEUTIC CLASS

Spironolactone vs placebo, Bisoprolol, and Doxazin to Determine the Optimal Treatment for drug-resistant Hypertention (PATHWAY-2) : a randomized, double blind, crossover trial.

Bryan Williams - Personal Name;

Optimal drug treatment for patients with resistant hypertension is undefi ned. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood pressure.

Availability

Location name is not set Location name is not set

REQJ312

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: Therapeutic Class
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Cardiovascular & Hematopoeiteic System
Spironolakton
B Beta
Specific Detail Info: The Lancet
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

Read Here

Comments

You must be logged in to post a comment